Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2419927rdf:typepubmed:Citationlld:pubmed
pubmed-article:2419927lifeskim:mentionsumls-concept:C0006467lld:lifeskim
pubmed-article:2419927lifeskim:mentionsumls-concept:C0282151lld:lifeskim
pubmed-article:2419927lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:2419927lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:2419927pubmed:issue12lld:pubmed
pubmed-article:2419927pubmed:dateCreated1986-4-9lld:pubmed
pubmed-article:2419927pubmed:abstractTextThe displacing potency of four analogs of the neuroleptic drug butaclamol were evaluated using dog striatal tissue and [3H]-Spiroperidol as ligand. Although significantly less powerful than the parent compound, two of them (N-isobutyl butaclamol equatorial; N-methyl butaclamol equatorial) could be used for dopaminergic receptor studies.lld:pubmed
pubmed-article:2419927pubmed:languageenglld:pubmed
pubmed-article:2419927pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2419927pubmed:citationSubsetIMlld:pubmed
pubmed-article:2419927pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2419927pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2419927pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2419927pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2419927pubmed:statusMEDLINElld:pubmed
pubmed-article:2419927pubmed:monthDeclld:pubmed
pubmed-article:2419927pubmed:issn0031-6989lld:pubmed
pubmed-article:2419927pubmed:authorpubmed-author:ColluRRlld:pubmed
pubmed-article:2419927pubmed:authorpubmed-author:DugasHHlld:pubmed
pubmed-article:2419927pubmed:authorpubmed-author:BasakAAlld:pubmed
pubmed-article:2419927pubmed:authorpubmed-author:BouvierCClld:pubmed
pubmed-article:2419927pubmed:issnTypePrintlld:pubmed
pubmed-article:2419927pubmed:volume17lld:pubmed
pubmed-article:2419927pubmed:ownerNLMlld:pubmed
pubmed-article:2419927pubmed:authorsCompleteYlld:pubmed
pubmed-article:2419927pubmed:pagination1153-7lld:pubmed
pubmed-article:2419927pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2419927pubmed:meshHeadingpubmed-meshheading:2419927-...lld:pubmed
pubmed-article:2419927pubmed:meshHeadingpubmed-meshheading:2419927-...lld:pubmed
pubmed-article:2419927pubmed:meshHeadingpubmed-meshheading:2419927-...lld:pubmed
pubmed-article:2419927pubmed:meshHeadingpubmed-meshheading:2419927-...lld:pubmed
pubmed-article:2419927pubmed:meshHeadingpubmed-meshheading:2419927-...lld:pubmed
pubmed-article:2419927pubmed:meshHeadingpubmed-meshheading:2419927-...lld:pubmed
pubmed-article:2419927pubmed:meshHeadingpubmed-meshheading:2419927-...lld:pubmed
pubmed-article:2419927pubmed:meshHeadingpubmed-meshheading:2419927-...lld:pubmed
pubmed-article:2419927pubmed:meshHeadingpubmed-meshheading:2419927-...lld:pubmed
pubmed-article:2419927pubmed:meshHeadingpubmed-meshheading:2419927-...lld:pubmed
pubmed-article:2419927pubmed:year1985lld:pubmed
pubmed-article:2419927pubmed:articleTitleDopaminergic activity of four analogs of butaclamol.lld:pubmed
pubmed-article:2419927pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2419927pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed